help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Miyazaki, Y.
Right arrow Articles by DeFronzo, R. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Miyazaki, Y.
Right arrow Articles by DeFronzo, R. A.
The Journal of Clinical Endocrinology & Metabolism Vol. 87, No. 6 2784-2791
Copyright © 2002 by The Endocrine Society

Endocrine Care

Effect of Pioglitazone on Abdominal Fat Distribution and Insulin Sensitivity in Type 2 Diabetic Patients

Yoshinori Miyazaki, Archana Mahankali, Masafumi Matsuda, Srikanth Mahankali, Jean Hardies, Kenneth Cusi, Lawrence J. Mandarino and Ralph A. DeFronzo

University of Texas Health Science Center and Texas Diabetes Institute, San Antonio, Texas 78229

Address all correspondence and requests for reprints to: Ralph A DeFronzo, M.D., Diabetes Division, University of Texas Health Science Center, Room 3.380S, 7703 Floyd Curl Drive, San Antonio, Texas 78229-3900. E-mail: . albarado{at}uthscsa.edu

Abstract

We examined the effect of pioglitazone on abdominal fat distribution to elucidate the mechanisms via which pioglitazone improves insulin resistance in patients with type 2 diabetes mellitus. Thirteen type 2 diabetic patients (nine men and four women; age, 52 ± 3 yr; body mass index, 29.0 ± 1.1 kg/m2), who were being treated with a stable dose of sulfonylurea (n = 7) or with diet alone (n = 6), received pioglitazone (45 mg/d) for 16 wk. Before and after pioglitazone treatment, subjects underwent a 75-g oral glucose tolerance test (OGTT) and two-step euglycemic insulin clamp (insulin infusion rates, 40 and 160 mU/m2·min) with [3H]glucose. Abdominal fat distribution was evaluated using magnetic resonance imaging at L4–5. After 16 wk of pioglitazone treatment, fasting plasma glucose (179 ± 10 to 140 ± 10 mg/dl; P < 0.01), mean plasma glucose during OGTT (295 ± 13 to 233 ± 14 mg/dl; P < 0.01), and hemoglobin A1c (8.6 ± 0.4% to 7.2 ± 0.5%; P < 0.01) decreased without a change in fasting or post-OGTT insulin levels. Fasting plasma FFA (674 ± 38 to 569 ± 31 µEq/liter; P < 0.05) and mean plasma FFA (539 ± 20 to 396 ± 29 µEq/liter; P < 0.01) during OGTT decreased after pioglitazone. In the postabsorptive state, hepatic insulin resistance [basal endogenous glucose production (EGP) x basal plasma insulin concentration] decreased from 41 ± 7 to 25 ± 3 mg/kg fat-free mass (FFM)·min x µU/ml; P < 0.05) and suppression of EGP during the first insulin clamp step (1.1 ± 0.1 to 0.6 ± 0.2 mg/kg FFM·min; P < 0.05) improved after pioglitazone treatment. The total body glucose MCR during the first and second insulin clamp steps increased after pioglitazone treatment [first MCR, 3.5 ± 0.5 to 4.4 ± 0.4 ml/kg FFM·min (P < 0.05); second MCR, 8.7 ± 1.0 to 11.3 ± 1.1 ml/kg FFM·min (P < 0.01)]. The improvement in hepatic and peripheral tissue insulin sensitivity occurred despite increases in body weight (82 ± 4 to 85 ± 4 kg; P < 0.05) and fat mass (27 ± 2 to 30 ± 3 kg; P < 0.05). After pioglitazone treatment, sc fat area at L4–5 (301 ± 44 to 342 ± 44 cm2; P < 0.01) increased, whereas visceral fat area at L4–5 (144 ± 13 to 131 ± 16 cm2; P < 0.05) and the ratio of visceral to sc fat (0.59 ± 0.08 to 0.44 ± 0.06; P < 0.01) decreased. In the postabsorptive state hepatic insulin resistance (basal EGP x basal immunoreactive insulin) correlated positively with visceral fat area (r = 0.55; P < 0.01). The glucose MCRs during the first (r = -0.45; P < 0.05) and second (r = -0.44; P < 0.05) insulin clamp steps were negatively correlated with the visceral fat area. These results demonstrate that a shift of fat distribution from visceral to sc adipose depots after pioglitazone treatment is associated with improvements in hepatic and peripheral tissue sensitivity to insulin.




This article has been cited by other articles:


Home page
 Mol. Endocrinol.Home page
F. M. Gregoire, F. Zhang, H. J. Clarke, T. A. Gustafson, D. D. Sears, S. Favelyukis, J. Lenhard, D. Rentzeperis, L. E. Clemens, Y. Mu, et al.
MBX-102/JNJ39659100, a Novel Peroxisome Proliferator-Activated Receptor-Ligand with Weak Transactivation Activity Retains Antidiabetic Properties in the Absence of Weight Gain and Edema
Mol. Endocrinol., July 1, 2009; 23(7): 975 - 988.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
H. Gotoh, T. Gohda, M. Tanimoto, Y. Gotoh, S. Horikoshi, and Y. Tomino
Contribution of subcutaneous fat accumulation to insulin resistance and atherosclerosis in haemodialysis patients
Nephrol. Dial. Transplant., June 17, 2009; (2009) gfp290v1.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
W. T. Festuccia, P.-G. Blanchard, V. Turcotte, M. Laplante, M. Sariahmetoglu, D. N. Brindley, and Y. Deshaies
Depot-specific effects of the PPAR{gamma} agonist rosiglitazone on adipose tissue glucose uptake and metabolism
J. Lipid Res., June 1, 2009; 50(6): 1185 - 1194.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
S. A. Porter, J. M. Massaro, U. Hoffmann, R. S. Vasan, C. J. O'Donnel, and C. S. Fox
Abdominal Subcutaneous Adipose Tissue: A Protective Fat Depot?
Diabetes Care, June 1, 2009; 32(6): 1068 - 1075.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
R. A. DeFronzo
From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus
Diabetes, April 1, 2009; 58(4): 773 - 795.
[Full Text] [PDF]

Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
M. Laplante, W. T. Festuccia, G. Soucy, P.-G. Blanchard, A. Renaud, J. P. Berger, G. Olivecrona, and Y. Deshaies
Tissue-specific postprandial clearance is the major determinant of PPAR{gamma}-induced triglyceride lowering in the rat
Am J Physiol Regulatory Integrative Comp Physiol, January 1, 2009; 296(1): R57 - R66.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
N. Anderson and J. Borlak
Molecular Mechanisms and Therapeutic Targets in Steatosis and Steatohepatitis
Pharmacol. Rev., September 1, 2008; 60(3): 311 - 357.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
B. Ravikumar, J. Gerrard, C. Dalla Man, M. J. Firbank, A. Lane, P. T. English, C. Cobelli, and R. Taylor
Pioglitazone Decreases Fasting and Postprandial Endogenous Glucose Production in Proportion to Decrease in Hepatic Triglyceride Content
Diabetes, September 1, 2008; 57(9): 2288 - 2295.
[Abstract] [Full Text] [PDF]

Home page
 J EndocrinolHome page
J. Takada, M. H. Fonseca-Alaniz, T. B. F. de Campos, S. Andreotti, A. B. Campana, M. Okamoto, C. d. N. Borges-Silva, U. F. Machado, and F. B. Lima
Metabolic recovery of adipose tissue is associated with improvement in insulin resistance in a model of experimental diabetes
J. Endocrinol., July 1, 2008; 198(1): 51 - 60.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
D. Glintborg, M. Andersen, C. Hagen, L. Heickendorff, and A. P. Hermann
Association of Pioglitazone Treatment with Decreased Bone Mineral Density in Obese Premenopausal Patients with Polycystic Ovary Syndrome: A Randomized, Placebo-Controlled Trial
J. Clin. Endocrinol. Metab., May 1, 2008; 93(5): 1696 - 1701.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
J. Y. Park, A. Y. Chong, E. K. Cochran, D. E. Kleiner, M. J. Haller, D. A. Schatz, and P. Gorden
Type 1 Diabetes Associated with Acquired Generalized Lipodystrophy and Insulin Resistance: The Effect of Long-Term Leptin Therapy
J. Clin. Endocrinol. Metab., January 1, 2008; 93(1): 26 - 31.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
R. Basu, P. Shah, A. Basu, B. Norby, B. Dicke, V. Chandramouli, O. Cohen, B. R. Landau, and R. A. Rizza
Comparison of the Effects of Pioglitazone and Metformin on Hepatic and Extra-Hepatic Insulin Action in People With Type 2 Diabetes
Diabetes, January 1, 2008; 57(1): 24 - 31.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. I. Anghel, E. Bedu, C. D. Vivier, P. Descombes, B. Desvergne, and W. Wahli
Adipose Tissue Integrity as a Prerequisite for Systemic Energy Balance: A CRITICAL ROLE FOR PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR {gamma}
J. Biol. Chem., October 12, 2007; 282(41): 29946 - 29957.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes and Vascular Disease ResearchHome page
V. Singaram and R. Pratley
The PROactive trial (PROspective pioglitAzone Clinical Trial In macroVascular Events): what does it mean for primary care physicians?
Diabetes and Vascular Disease Research, September 1, 2007; 4(3): 237 - 240.
[Abstract] [PDF]

Home page
 Eur J EndocrinolHome page
S.-K. Kim, K.-Y. Hur, H.-J. Kim, W.-S. Shim, C.-W. Ahn, S.-W. Park, Y.-W. Cho, S.-K. Lim, H.-C. Lee, and B.-S. Cha
The increase in abdominal subcutaneous fat depot is an independent factor to determine the glycemic control after rosiglitazone treatment
Eur. J. Endocrinol., August 1, 2007; 157(2): 167 - 174.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
V. Varma, A. Yao-Borengasser, N. Rasouli, A. M. Bodles, B. Phanavanh, M.-J. Lee, T. Starks, L. M. Kern, H. J. Spencer III, R. E. McGehee Jr., et al.
Human Visfatin Expression: Relationship to Insulin Sensitivity, Intramyocellular Lipids, and Inflammation
J. Clin. Endocrinol. Metab., February 1, 2007; 92(2): 666 - 672.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. M. Sharma and B. Staels
Peroxisome Proliferator-Activated Receptor {gamma} and Adipose Tissue--Understanding Obesity-Related Changes in Regulation of Lipid and Glucose Metabolism
J. Clin. Endocrinol. Metab., February 1, 2007; 92(2): 386 - 395.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
J. D. Brown and J. Plutzky
Peroxisome Proliferator Activated Receptors as Transcriptional Nodal Points and Therapeutic Targets
Circulation, January 30, 2007; 115(4): 518 - 533.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
A. Karim, M. Slater, D. Bradford, L. Schwartz, Z. Zhao, C. Cao, and A. Laurent
Oral Antidiabetic Drugs: Bioavailability Assessment of Fixed-Dose Combination Tablets of Pioglitazone and Metformin. Effect of Body Weight, Gender, and Race on Systemic Exposures of Each Drug
J. Clin. Pharmacol., January 1, 2007; 47(1): 37 - 47.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
S. E. Kahn, S. M. Haffner, M. A. Heise, W. H. Herman, R. R. Holman, N. P. Jones, B. G. Kravitz, J. M. Lachin, M. C. O'Neill, B. Zinman, et al.
Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy
N. Engl. J. Med., December 7, 2006; 355(23): 2427 - 2443.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
K. M. Utzschneider and S. E. Kahn
The Role of Insulin Resistance in Nonalcoholic Fatty Liver Disease
J. Clin. Endocrinol. Metab., December 1, 2006; 91(12): 4753 - 4761.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
R. Belfort, S. A. Harrison, K. Brown, C. Darland, J. Finch, J. Hardies, B. Balas, A. Gastaldelli, F. Tio, J. Pulcini, et al.
A Placebo-Controlled Trial of Pioglitazone in Subjects with Nonalcoholic Steatohepatitis
N. Engl. J. Med., November 30, 2006; 355(22): 2297 - 2307.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
G. Ranganathan, R. Unal, I. Pokrovskaya, A. Yao-Borengasser, B. Phanavanh, B. Lecka-Czernik, N. Rasouli, and P. A. Kern
The lipogenic enzymes DGAT1, FAS, and LPL in adipose tissue: effects of obesity, insulin resistance, and TZD treatment
J. Lipid Res., November 1, 2006; 47(11): 2444 - 2450.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
C. Triplitt, L. Glass, Y. Miyazaki, E. Wajcberg, A. Gastaldelli, E. De Filippis, E. Cersosimo, and R. A. DeFronzo
Comparison of glargine insulin versus rosiglitazone addition in poorly controlled type 2 diabetic patients on metformin plus sulfonylurea.
Diabetes Care, November 1, 2006; 29(11): 2371 - 2377.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
A. Gastaldelli, Y. Miyazaki, A. Mahankali, R. Berria, M. Pettiti, E. Buzzigoli, E. Ferrannini, and R. A. DeFronzo
The Effect of Pioglitazone on the Liver: Role of adiponectin
Diabetes Care, October 1, 2006; 29(10): 2275 - 2281.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
M. Laplante, W. T. Festuccia, G. Soucy, Y. Gelinas, J. Lalonde, J. P. Berger, and Y. Deshaies
Mechanisms of the Depot Specificity of Peroxisome Proliferator-Activated Receptor {gamma} Action on Adipose Tissue Metabolism.
Diabetes, October 1, 2006; 55(10): 2771 - 2778.
[Abstract] [Full Text] [PDF]

Home page
 British Journal of Diabetes & Vascular DiseaseHome page
I. W Campbell
The role of metformin and pioglitazone in early combination treatment of type 2 diabetes mellitus
The British Journal of Diabetes & Vascular Disease, September 1, 2006; 6(5): 207 - 215.
[Abstract] [PDF]

Home page
 DiabetesHome page
S. E. Kahn, B. Zinman, S. M. Haffner, M. C. O'Neill, B. G. Kravitz, D. Yu, M. I. Freed, W. H. Herman, R. R. Holman, N. P. Jones, et al.
Obesity is a major determinant of the association of C-reactive protein levels and the metabolic syndrome in type 2 diabetes.
Diabetes, August 1, 2006; 55(8): 2357 - 2364.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
K. Araki, T. Masaki, I. Katsuragi, K. Tanaka, T. Kakuma, and H. Yoshimatsu
Telmisartan Prevents Obesity and Increases the Expression of Uncoupling Protein 1 in Diet-Induced Obese Mice
Hypertension, July 1, 2006; 48(1): 51 - 57.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
A. Basu, M. D. Jensen, F. McCann, D. Mukhopadhyay, M. J. Joyner, and R. A. Rizza
Effects of pioglitazone versus glipizide on body fat distribution, body water content, and hemodynamics in type 2 diabetes.
Diabetes Care, March 1, 2006; 29(3): 510 - 514.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. Gastaldelli, Y. Miyazaki, M. Pettiti, E. Santini, D. Ciociaro, R. A. DeFronzo, and E. Ferrannini
The Effect of Rosiglitazone on the Liver: Decreased Gluconeogenesis in Patients with Type 2 Diabetes
J. Clin. Endocrinol. Metab., March 1, 2006; 91(3): 806 - 812.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
N. Rasouli, A. Yao-Borengasser, L. M. Miles, S. C. Elbein, and P. A. Kern
Increased plasma adiponectin in response to pioglitazone does not result from increased gene expression
Am J Physiol Endocrinol Metab, January 1, 2006; 290(1): E42 - E46.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
D. Glintborg, R. K. Stoving, C. Hagen, A. P. Hermann, J. Frystyk, J. D. Veldhuis, A. Flyvbjerg, and M. Andersen
Pioglitazone Treatment Increases Spontaneous Growth Hormone (GH) Secretion and Stimulated GH Levels in Polycystic Ovary Syndrome
J. Clin. Endocrinol. Metab., October 1, 2005; 90(10): 5605 - 5612.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
H. E. Lebovitz and M. A. Banerji
Point: Visceral Adiposity Is Causally Related to Insulin Resistance
Diabetes Care, September 1, 2005; 28(9): 2322 - 2325.
[Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
M. Oette, M. Kurowski, T. Feldt, A. Kroidl, A. Sagir, C. Vogt, M. Wettstein, and D. Haussinger
Impact of rosiglitazone treatment on the bioavailability of antiretroviral compounds in HIV-positive patients
J. Antimicrob. Chemother., August 1, 2005; 56(2): 416 - 419.
[Abstract] [Full Text] [PDF]

Home page
 British Journal of Diabetes & Vascular DiseaseHome page
I. W Campbell
Pioglitazone -- an oral antidiabetic agent and metabolic syndrome modulator. Can theory translate into practice?
The British Journal of Diabetes & Vascular Disease, July 1, 2005; 5(4): 209 - 216.
[Abstract] [PDF]

Home page
 Cardiovasc ResHome page
M. Abdelrahman, A. Sivarajah, and C. Thiemermann
Beneficial effects of PPAR-{gamma} ligands in ischemia-reperfusion injury, inflammation and shock
Cardiovasc Res, March 1, 2005; 65(4): 772 - 781.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
G. Schernthaner, D. R. Matthews, B. Charbonnel, M. Hanefeld, P. Brunetti, and on Behalf of the Quarter Study Group
Efficacy and Safety of Pioglitazone Versus Metformin in Patients with Type 2 Diabetes Mellitus: A Double-Blind, Randomized Trial
J. Clin. Endocrinol. Metab., December 1, 2004; 89(12): 6068 - 6076.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
E. Chiquette, G. Ramirez, and R. DeFronzo
A Meta-analysis Comparing the Effect of Thiazolidinediones on Cardiovascular Risk Factors
Arch Intern Med, October 25, 2004; 164(19): 2097 - 2104.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
H. Yki-Jarvinen
Thiazolidinediones
N. Engl. J. Med., September 9, 2004; 351(11): 1106 - 1118.
[Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
Y. Miyazaki, A. Mahankali, E. Wajcberg, M. Bajaj, L. J. Mandarino, and R. A. DeFronzo
Effect of Pioglitazone on Circulating Adipocytokine Levels and Insulin Sensitivity in Type 2 Diabetic Patients
J. Clin. Endocrinol. Metab., September 1, 2004; 89(9): 4312 - 4319.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
M. Tiikkainen, A.-M. Hakkinen, E. Korsheninnikova, T. Nyman, S. Makimattila, and H. Yki-Jarvinen
Effects of Rosiglitazone and Metformin on Liver Fat Content, Hepatic Insulin Resistance, Insulin Clearance, and Gene Expression in Adipose Tissue in Patients With Type 2 Diabetes
Diabetes, August 1, 2004; 53(8): 2169 - 2176.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
R. M. Krauss
Lipids and Lipoproteins in Patients With Type 2 Diabetes
Diabetes Care, June 1, 2004; 27(6): 1496 - 1504.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
J. Tonelli, W. Li, P. Kishore, U. B. Pajvani, E. Kwon, C. Weaver, P. E. Scherer, and M. Hawkins
Mechanisms of Early Insulin-Sensitizing Effects of Thiazolidinediones in Type 2 Diabetes
Diabetes, June 1, 2004; 53(6): 1621 - 1629.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
I. Lemieux
Energy Partitioning in Gluteal-Femoral Fat: Does the Metabolic Fate of Triglycerides Affect Coronary Heart Disease Risk?
Arterioscler. Thromb. Vasc. Biol., May 1, 2004; 24(5): 795 - 797.
[Full Text]

Home page
 J. Clin. Endocrinol. Metab.Home page
H. Bays, L. Mandarino, and R. A. DeFronzo
Role of the Adipocyte, Free Fatty Acids, and Ectopic Fat in Pathogenesis of Type 2 Diabetes Mellitus: Peroxisomal Proliferator-Activated Receptor Agonists Provide a Rational Therapeutic Approach
J. Clin. Endocrinol. Metab., February 1, 2004; 89(2): 463 - 478.
[Full Text] [PDF]

Home page
 Am. J. Clin. Nutr.Home page
M. Tiikkainen, R. Bergholm, A. Rissanen, A. Aro, I. Salminen, M. Tamminen, K. Teramo, and H. Yki-Jarvinen
Effects of equal weight loss with orlistat and placebo on body fat and serum fatty acid composition and insulin resistance in obese women
Am. J. Clinical Nutrition, January 1, 2004; 79(1): 22 - 30.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. Bajaj, S. Suraamornkul, P. Piper, L. J. Hardies, L. Glass, E. Cersosimo, T. Pratipanawatr, Y. Miyazaki, and R. A. DeFronzo
Decreased Plasma Adiponectin Concentrations Are Closely Related to Hepatic Fat Content and Hepatic Insulin Resistance in Pioglitazone-Treated Type 2 Diabetic Patients
J. Clin. Endocrinol. Metab., January 1, 2004; 89(1): 200 - 206.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
M. Hanefeld, P. Brunetti, G. H. Schernthaner, D. R. Matthews, and B. H. Charbonnel
One-Year Glycemic Control With a Sulfonylurea Plus Pioglitazone Versus a Sulfonylurea Plus Metformin in Patients With Type 2 Diabetes
Diabetes Care, January 1, 2004; 27(1): 141 - 147.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
R. W. Nesto, D. Bell, R. O. Bonow, V. Fonseca, S. M. Grundy, E. S. Horton, M. Le Winter, D. Porte, C. F. Semenkovich, S. Smith, et al.
Thiazolidinedione Use, Fluid Retention, and Congestive Heart Failure: A consensus statement from the American Heart Association and American Diabetes Association
Diabetes Care, January 1, 2004; 27(1): 256 - 263.
[Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
A. R. Diani, G. Sawada, B. Wyse, F. T. Murray, and M. Khan
Pioglitazone preserves pancreatic islet structure and insulin secretory function in three murine models of type 2 diabetes
Am J Physiol Endocrinol Metab, January 1, 2004; 286(1): E116 - E122.
[Abstract] [Full Text]

Home page
 CirculationHome page
R. W. Nesto, D. Bell, R. O. Bonow, V. Fonseca, S. M. Grundy, E. S. Horton, M. Le Winter, D. Porte, C. F. Semenkovich, S. Smith, et al.
Thiazolidinedione Use, Fluid Retention, and Congestive Heart Failure: A Consensus Statement From the American Heart Association and American Diabetes Association
Circulation, December 9, 2003; 108(23): 2941 - 2948.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
S. Shadid and M. D. Jensen
Effects of Pioglitazone Versus Diet and Exercise on Metabolic Health and Fat Distribution in Upper Body Obesity
Diabetes Care, November 1, 2003; 26(11): 3148 - 3152.
[Abstract] [Full Text] [PDF]

Home page
 J. Nutr.Home page
T. Mae, H. Kishida, T. Nishiyama, M. Tsukagawa, E. Konishi, M. Kuroda, Y. Mimaki, Y. Sashida, K. Takahashi, T. Kawada, et al.
A Licorice Ethanolic Extract with Peroxisome Proliferator-Activated Receptor-{gamma} Ligand-Binding Activity Affects Diabetes in KK-Ay Mice, Abdominal Obesity in Diet-Induced Obese C57BL Mice and Hypertension in Spontaneously Hypertensive Rats
J. Nutr., November 1, 2003; 133(11): 3369 - 3377.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
V. De Leo, A. la Marca, and F. Petraglia
Insulin-Lowering Agents in the Management of Polycystic Ovary Syndrome
Endocr. Rev., October 1, 2003; 24(5): 633 - 667.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
Y. Miyazaki, H. He, L. J. Mandarino, and R. A. DeFronzo
Rosiglitazone Improves Downstream Insulin Receptor Signaling in Type 2 Diabetic Patients
Diabetes, August 1, 2003; 52(8): 1943 - 1950.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
M. Bajaj, S. Suraamornkul, T. Pratipanawatr, L. J. Hardies, W. Pratipanawatr, L. Glass, E. Cersosimo, Y. Miyazaki, and R. A. DeFronzo
Pioglitazone Reduces Hepatic Fat Content and Augments Splanchnic Glucose Uptake in Patients With Type 2 Diabetes
Diabetes, June 1, 2003; 52(6): 1364 - 1370.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
I. Pavo, G. Jermendy, T. T. Varkonyi, Z. Kerenyi, A. Gyimesi, S. Shoustov, M. Shestakova, M. Herz, D. Johns, B. J. Schluchter, et al.
Effect of Pioglitazone Compared with Metformin on Glycemic Control and Indicators of Insulin Sensitivity in Recently Diagnosed Patients with Type 2 Diabetes
J. Clin. Endocrinol. Metab., April 1, 2003; 88(4): 1637 - 1645.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
D. B. Savage, G. D. Tan, C. L. Acerini, S. A. Jebb, M. Agostini, M. Gurnell, R. L. Williams, A. M. Umpleby, E. L. Thomas, J. D. Bell, et al.
Human Metabolic Syndrome Resulting From Dominant-Negative Mutations in the Nuclear Receptor Peroxisome Proliferator-Activated Receptor-{gamma}
Diabetes, April 1, 2003; 52(4): 910 - 917.
[Abstract] [Full Text] [PDF]

Home page
 Mayo Clin Proc.Home page
F. Zangeneh, Y. C. Kudva, and A. Basu
Insulin Sensitizers
Mayo Clin. Proc., April 1, 2003; 78(4): 471 - 479.
[Abstract] [PDF]

Home page
 Arch Intern MedHome page
J. O. Hill and D. Bessesen
What to Do About the Metabolic Syndrome?
Arch Intern Med, February 24, 2003; 163(4): 395 - 397.
[Full Text] [PDF]

Home page
 DiabetesHome page
K. A. Virtanen, K. Hallsten, R. Parkkola, T. Janatuinen, F. Lonnqvist, T. Viljanen, T. Ronnemaa, J. Knuuti, R. Huupponen, P. Lonnroth, et al.
Differential Effects of Rosiglitazone and Metformin on Adipose Tissue Distribution and Glucose Uptake in Type 2 Diabetic Subjects
Diabetes, February 1, 2003; 52(2): 283 - 290.
[Abstract] [Full Text] [PDF]

Home page
 British Journal of Diabetes & Vascular DiseaseHome page
R. A Defronzo
Impaired glucose tolerance: do pharmacological therapies correct the underlying metabolic disturbance?
The British Journal of Diabetes & Vascular Disease, January 1, 2003; 3(1_suppl): S24 - S40.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2002 by The Endocrine Society